So if the first licensing deal for UK, Switzerland, Canada, NZ...

So if the first licensing deal for UK, Switzerland, Canada, NZ and Australia was valued $230M PLUS ongoing royalties in the mid-teens to 20% and this is only 20% of the global market then you possibly are looking at circa $1Billion in licensing deals plus ongoing royalties. Where do we think the SP will go if we pull in $1 Billion in licensing deals when we are sitting on a measly $91M market cap?

To get an understanding of an example of where this could all go, China- as a separate region - has accepted our Investigational New Drug Application. If DMX-200 is taken up in China, with the market there for FSGS disease valued at $2.2 billion then you can imagine what the possible annual royalties from this region alone would mean for the value of the company. I would suggest the SP would in that situation be in many multiples from here....

When Nina says they have been very busy working on licensing deals (plural) (aside from what has been achieved), it makes you wonder when the next one/s will be announced...Its just my personal opinion but I reckon that if there was any hint on the current phase 3 trials not panning out they would not be aggressively pursuing global licensing deals, nor would Advanz Pharma have gone ahead with entering into a deal and parting with $10.8 million straight up. All just my opinion. Good luck all...